Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Erica Severson"'
Autor:
Amanda McIver, Andrzej Jakubowiak, Agata Turowski, Ajai Chari, Erica Severson, Shaun Rosebeck, Joseph R. Mikhael, Jeffrey A. Zonder, Jennifer Nam, Kathryn M. Tinari, Todd M. Zimmerman, Leonor A Stephens, Theodore Karrison, Tyler Hycner, Jagoda Jasielec, Craig E. Cole, Cara A. Rosenbaum
Publikováno v:
British Journal of Haematology
Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO1, also termed CRM1). Non‐clinical studies support combining selinexor with proteasome inhibitors (PIs) and corticosteroids to overcome resistance in relapsed/refracto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2798c93f6b60440c07bc3531ca50a4d
https://pubmed.ncbi.nlm.nih.gov/31124580
https://pubmed.ncbi.nlm.nih.gov/31124580
Autor:
Kathryn McDonnell, Shaun Rosebeck, Donna E. Reece, Andrew T. Stefka, Sandeep Gurbuxani, Ravi Vij, Cara A. Rosenbaum, Leonor A Stephens, Kent A. Griffith, Jagoda Jasielec, Paul G. Richardson, Brittany Wolfe, Noopur Raje, Jennifer Nam, Dominik Dytfeld, Andrzej Jakubowiak, Todd M. Zimmerman, Erica Severson, Jesus G. Berdeja
Publikováno v:
Blood. 128:675-675
Introduction In a phase 1/2 study designed to assess KRd w/o ASCT, KRd provided a high rate of stringent complete response (sCR) (55%) in NDMM patients (pts) after a median of 24 cycles and 47.5 months (mo) of follow-up (f/u), with 4-year (yr) progre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14851c6221c4e6ce1f3dfbb3621195a4
https://doi.org/10.1182/blood.v128.22.675.675
https://doi.org/10.1182/blood.v128.22.675.675
Autor:
Jeffrey A. Zonder, Kathryn McDonnell, Todd M. Zimmerman, Leonor A Stephens, Jennifer Nam, Andrzej Jakubowiak, Theodore Karrison, Cara A. Rosenbaum, Jagoda Jasielec, Shaun Rosebeck, Craig E. Cole, Ajai Chari, Erica Severson
Publikováno v:
Blood. 128:973-973
Background There are an increasing number of multiple myeloma (MM) patients (pts) refractory to currently available drugs, including the proteasome inhibitors bortezomib and carfilzomib (CFZ), necessitating development of novel therapeutics. Pre-clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5a76d17d3853bc7aacf6a1d49240b14
https://doi.org/10.1182/blood.v128.22.973.973
https://doi.org/10.1182/blood.v128.22.973.973
Autor:
Kathryn McDonnell, Kent A. Griffith, Erica Severson, Todd M. Zimmerman, Cara A. Rosenbaum, Andrzej Jakubowiak, Vishal Kukreti, Leonor A Stephens, Craig E. Cole, Jeffrey A. Zonder, Jesus G. Berdeja, Donna E. Reece, Jennifer Nam, Brittany Wolfe, Andrea Revethis
Publikováno v:
Journal of Clinical Oncology. 34:8007-8007
8007Background: The combination of carfilzomib (CFZ), pomalidomide (POM) and dexamethasone (DEX) showed very promising activity in advanced RRMM. In this phase 1/2 study, KPd was evaluated in less-...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e641f3221abf508e2053348d13d0af35
https://doi.org/10.1200/jco.2016.34.15_suppl.8007
https://doi.org/10.1200/jco.2016.34.15_suppl.8007